Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OSBP | P22059 | 3/20 | 0.79 |
| ▸ | RORC | P51449 | 2/20 | 0.79 |
| ▸ | USP2 | O75604 | 1/20 | 0.79 |
| ▸ | LMNA | P02545 | 1/20 | 0.79 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.79 |
| ▸ | OSBP2 | Q969R2 | 1/20 | 0.79 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.79 |
| ▸ | NR1H3 | Q13133 | 6/20 | 0.77 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.77 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.68 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.68 |
| ▸ | NPC1L1 | Q9UHC9 | 2/20 | 0.67 |
| ▸ | POLA1 | P09884 | 1/20 | 0.67 |
| ▸ | DHCR24 | Q15392 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cholesterol SCHEMBL9566174 | 1.00 | OSBP (0.79) | OSBPRORCUSP2LMNAABCB1 | |
| Cholesterol SCHEMBL7736671 | 1.00 | OSBP (0.79) | OSBPRORCUSP2LMNAABCB1 | |
| Cholesterol SCHEMBL161748 | 1.00 | OSBP (0.79) | OSBPRORCUSP2LMNAABCB1 | |
| Cholesterol SCHEMBL2195602 | 1.00 | OSBP (0.79) | OSBPRORCUSP2LMNAABCB1 | |
| Cholesterol SCHEMBL10933840 | 1.00 | OSBP (0.79) | OSBPRORCUSP2LMNAABCB1 | |
| Cholesterol SCHEMBL25174230 | 1.00 | OSBP (0.79) | OSBPRORCUSP2LMNAABCB1 | |
| Cholesterol SCHEMBL16415838 | 1.00 | OSBP (0.79) | OSBPRORCUSP2LMNAABCB1 | |
| Cholesterol SCHEMBL10883099 | 1.00 | OSBP (0.79) | OSBPRORCUSP2LMNAABCB1 | |
| Cholesterol SCHEMBL22749559 | 1.00 | OSBP (0.79) | OSBPRORCUSP2LMNAABCB1 | |
| Cholesterol SCHEMBL892123 | 1.00 | OSBP (0.79) | OSBPRORCUSP2LMNAABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 166 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025133105-A1 | COMPOSITIONS AND METHODS | BIONTECH DELIVERY TECHNOLOGIES GMBH (DE) | 2025-06-26 | — | — | WO | claimed |
| US-12233034-B2 | Formulations for epidermal repair | CLARIDEI LABORATORIES, INC. (US) | 2025-02-25 | — | — | US | claimed |
| CN-118525997-A | Antibacterial and antiviral atomizer for electronic atomizer and preparation method thereof | 深圳市卓力能技术有限公司 | 2024-08-23 | — | — | CN | claimed |
| CN-115461096-A | Polymer encapsulated drug particles | 吉益医疗公司 | 2022-12-09 | — | — | CN | claimed |
| US-20220031640-A1 | FORMULATIONS FOR EPIDURAL REPAIR | CLARIDEI LABORATORIES, INC. | 2022-02-03 | — | — | US | claimed |
| US-11135184-B2 | Formulations for epidermal repair | CLARIDEI LABORATORIES, INC. (US) | 2021-10-05 | — | — | US | claimed |
| CN-108815134-B | Preparation and application of biological camouflage targeted nano drug delivery system for treating ischemic stroke | 中国药科大学 | 2021-07-13 | — | — | CN | claimed |
| US-20180289642-A1 | FORMULATIONS FOR EPIDERMAL REPAIR | CLARIDEI LABORATORIES, INC. | 2018-10-11 | — | — | US | claimed |
| CN-105792810-A | Formula for epidermis repair | 绮丽儿·李·艾柏汀 | 2016-07-20 | — | — | CN | claimed |
| US-20160184245-A1 | FORMULATIONS FOR EPIDERMAL REPAIR | CLARIDEI LABORATORIES, INC. | 2016-06-30 | — | — | US | claimed |
| EP-3024438-A1 | FORMULATIONS FOR EPIDERMAL REPAIR | Eberting, Cheryl Lee (US) | 2016-06-01 | — | — | EP | claimed |
| CN-104672311-A | Lipopeptides for delivery of nucleic acids | MARINA BIOTECH INC | 2015-06-03 | — | — | CN | claimed |
| WO-2015013634-A1 | FORMULATIONS FOR EPIDERMAL REPAIR | EBERTING CHERYL LEE (US) | 2015-01-29 | — | — | WO | claimed |
| CN-101939027-B | Lipopeptides for delivery of nucleic acids | MDRNA INC | 2014-07-30 | — | — | CN | claimed |
| CN-102741336-B | Modified rubber composition and preparation method | BRIDGESTONE CORP | 2014-03-19 | — | — | CN | claimed |
| CN-102741336-A | Modified rubber composition and preparation method | BRIDGESTONE CORP | 2012-10-17 | — | — | CN | claimed |
| CN-102027019-A | High density lipoprotein-like peptide phospholipid scaffold (\"HPPS\") nanoparticles | UNIV HEALTH NETWORK | 2011-04-20 | — | — | CN | claimed |
| CN-101939027-A | Lipopeptides for delivery of nucleic acids | MDRNA INC | 2011-01-05 | — | — | CN | claimed |
| US-5885565-A | APPLYING TO THE EPITHELIUM OF THE HOST, AN EFFECTIVE AMOUNT OF ONE OR MORE PENETRATION ENHANCING EPITHELIAL STEROLS AND THERAPEUTICAL OR PROPHYLACTIC AGENT | CELLEGY PHARMACEUTICALS INC. (US) | 1999-03-23 | — | — | US | claimed |
| US-4011138-A | FERMENTATION OF PSEUDOMONAS | KYOWA HAKKO KOGYO CO., LTD. (JA) | 1977-03-08 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12233034-B2 | Formulations for epidermal repair | KRT18, CUTA, DSG1 | OSBP 857/4885RORC 356/4885USP2 1927/4885 |
| US-20180289642-A1 | FORMULATIONS FOR EPIDERMAL REPAIR | KRT18, CUTA, DSG1 | OSBP 975/4885RORC 377/4885USP2 1921/4885 |
| US-20160184245-A1 | FORMULATIONS FOR EPIDERMAL REPAIR | KRT18, CUTA, DSG1 | OSBP 857/4885RORC 356/4885USP2 1927/4885 |
| US-20220031640-A1 | FORMULATIONS FOR EPIDURAL REPAIR | CUTA, EPHB1, EPHB2 | OSBP 780/4885RORC 281/4885USP2 2428/4885 |
| US-11135184-B2 | Formulations for epidermal repair | KRT18, CUTA, DSG1 | OSBP 857/4885RORC 356/4885USP2 1927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.